Abstract 102P
Background
Acute lymphoblastic leukemia is the most common type of cancer among children. Around 20% of patients relapse after remission. Minimal residual disease (MRD) is used as a predictor of relapse. MDR is measured by flow cytometry in bone marrow samples. MicroRNAs are small non-coding RNAs that regulate gene expression, acting as oncogenic or tumor suppressor biomolecules. MicroRNAs are secreted in various biofluids, including urine or saliva, at levels that reflect the homeostatic state of an individual. These secreted microRNAs might be useful as non-invasive biomarkers of MRD and treatment follow up in leukemia. This study aims to identify and evaluate the usefulness of urinary and salivary microRNAs as biomarkers of MRD in children diagnosed with acute lymphoblastic leukemia.
Methods
Saliva and urine samples, from high (MRD≥10) and standard intermediate (MDR<10) risk of relapse children, were collected on day 15 of chemotherapy. MicroRNAs were extracted using a commercial kit and sequenced to identify differences in secretion patterns. Differential expression analysis was carried out using the DeSeq2 algorithm.
Results
The mean MRD on day 15 was 52.23 % ± 38.42 and 1.03 % ± 0.53 in the high risk and standard intermediate risk children, respectively. Twenty-three microRNAs were differentially secreted (adjusted p-value < 0.01 and log 2 fold change > 1) between the high risk and standard intermediate children in saliva (12 upregulated and 11 downregulated). In contrast, only 3 sequences were differentially secreted (all downregulated) in urine samples. The miR-1246 and miR-3976 showed the highest increase (log 2 fold change = 7.53) and decrease (log 2 fold change = -5.52), respectively, in saliva samples. In urine miR-4783-5p showed the highest decrease (log 2 fold change = -3.15). However, these results need to be validated using PCR techniques.
Conclusions
In conclusion, miR-1246, miR-3976 and miR-4783-5p show promising utility as MRD biomarkers for monitoring MRD and treatment follow up in children diagnosed with ALL. With the additional advantage that microRNAs are more stable than other molecular markers and urine and saliva samples are non-invasive and easy to collect.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
FONDECYT-CONCYTEC (Grant Contract Number 165-2020-FONDECYT).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract